Click here to download high-res photos

Press Release
For Immediate Release

HKSTP Leads Largest-Ever Hong Kong Delegation to BIO 2026
Showcasing Life and Health Tech Strength

41 local tech firms, institutes and university spin-offs head to San Diego to forge global partnerships, reinforcing the city's status as international healthcare innovation hub

Key Takeaways:

- HKSTP joins forces with InvestHK and HKTDC at BIO 2026, and for the first time partnering with five renowned local universities (HKU, CUHK, HKUST, PolyU, and CityUHK) to form city's largest-ever life and health technology delegation.
- HKSTP and five Hong Kong university delegates visited the Salk Institute – home to six Nobel Laureates – during BIO 2026 to explore partnerships.
- The delegation witnessed the landmark signing of three MoUs, key milestones for HKSTP and its park companies in forging partnerships with leading global biotech partners. These include LabCentral, one of the world's largest non-profit biotech startup incubators; OPIS, an international clinical Contract Research Organization (CRO); and Laboratório Teuto Brasileiro S.A., the first company to produce generic and over-the-counter (OTC) medicines in Brazil.

(24 June 2026 - Hong Kong / San Diego) — Hong Kong Science and Technology Parks Corporation (HKSTP), in collaboration with InvestHK as co-organiser, the Hong Kong Trade Development Council (HKTDC) as supporting organisation, and five renowned local universities - The University of Hong Kong, The Chinese University of Hong Kong, The Hong Kong University of Science and Technology, The Hong Kong Polytechnic University and City University of Hong Kong - to form the city's largest-ever delegation of life and health technology innovators to the BIO International Convention 2026 (BIO 2026) in San Diego, from June 22 to 25.

Building on last year's momentum, the 2026 Hong Kong delegation doubled the size of the Hong Kong Pavilion, expanding to a record of 41 organisations from HKSTP, including partner companies, research institutes, and for the first time with top five universities spin-offs. This landmark presence showcased Hong Kong's deep strength across AI-enabled biotech, therapeutics, diagnostics, and pharma innovation, with potential outstanding "First-in-Class" and "Best-in-Class" assets. The delegation underscores the city's leading role as Asia's largest and the world's second largest fundraising hub for the biotechnology sector.

Mr. Terry Wong, CEO of HKSTP, said, "BIO 2026 is a premier platform to showcase Hong Kong's groundbreaking innovation, deepen partnerships, and open new pathways into global healthcare markets. As a super-connector, Hong Kong is uniquely positioned to bridge global innovators with opportunities

across Asia and beyond. With strong R&D capabilities backed by world-class universities—five ranked among the QS Top 100, including two with medical schools now placed in the global top 20—Hong Kong's biotech and medical research excellence is increasingly recognised worldwide. As the city's innovation ecosystem orchestrator, HKSTP brings together talent, capital, research institutions, clinical partners, and industry leaders to accelerate the journey from discovery to impact. We will continue to empower life and health technology ventures, translating innovation breakthroughs into life-changing solutions that benefit communities around the world."

HKSTP and Park Companies Advanced in Cross-border Innovation and Market Expansion

A key highlight of BIO 2026 is witnessing the signing of three major strategic partnerships:

- **LabCentral --** HKSTP signed an MOU with **one of the largest global non-profit biotech incubators**, supporting life sciences startups with high-impact lab infrastructure and scientific community programmes. The collaboration will deepen ties between the U.S. and Hong Kong life sciences ecosystems through startup support, ecosystem engagement, and co-developed programmes, events and strategic initiatives. It will also help connect startups, investors, corporate partners and research institutions, creating stronger pathways for cross-border innovation and commercialisation.

- **Immuno Cure** – the developer of the first-in-human novel therapeutic HIV vaccine ICVAX – announced its collaboration with OPIS, an international Contract Research Organization (CRO), at BIO 2026. Leveraging OPIS's full-service, multi-country clinical trial expertise and regulatory knowledge, the partnership will support overseas clinical trial execution and establish a global framework to prepare for international expansion.

- **Zhaoke Ophthalmology** signed an MOU with Laboratório Teuto, the first company to produce generic medicines and OTCs (Over the Counter – Prescription Exempt Medicines) in Brazil, to explore cross-border cooperation in ophthalmology. This is Zhaoke's first strategic MOU in Brazil market. Leveraging its innovative pipeline and Teuto's commercial network in Brazil, the partnership aims to bring advanced eye care treatments to Latin American patients while demonstrating the globalisation of Hong Kong-born biotech innovation.

Beyond the BIO 2026 Hong Kong Pavilion, HKSTP CEO Mr Terry Wong attended the "Translating Innovation Across Borders: Creating Global Gateways for Biotech Startups" panel sharing session. Mr. Wong shared his insights on cutting-edge biotech trends, Hong Kong's strengths on life and health tech development, and HKSTP's role in building a global bridge for nurturing global startup expansion, sustainable innovation and collaboration.

Furthermore, HKSTP and five Hong Kong university delegates visited the Salk Institute, home to six Nobel Laureates during BIO 2026 to explore partnerships and shape global biotech momentum through collaborative platforms. HKSTP, in collaboration with InvestHK as co-organiser, HKTDC as the supporting organisation, and powered by the Hong Kong Economic and Trade Office in San Francisco, hosted a Global Mixer during the exhibition. Industry leaders, incubators, and venture capital firms – including Bayer Pharmaceuticals, Johnson & Johnson Innovation, LabCentral, Roche, Simcere Pharmaceutical, and T.Rx Capital – were invited to join the judging panel for startup pitching sessions. The Pavilion also featured executive sharing and curated networking events for commercialisation, licensing, partnerships, investment and international market expansion.

Global recognition at Biomedical Pitch Competition

In the lead-up to BIO 2026, HKSTP actively drove engagement across the biotech sector and co-organised the 2026 Biomedical Pitch Competition with the Boston Capital Investment Club in Boston on May 23 and 24. Competing against around 170 biotechnology companies worldwide, HKSTP park company Meta Pharmaceuticals (HK) Limited won Third Place for its next-generation autoimmune therapeutics. The recognition underscores the strength of Hong Kong's biotech pipeline and HKSTP's commitment to translational medicine, commercialisation and globally scalable healthcare solutions.

HK's biotech ecosystem rises to another level

Hong Kong continues to expand its global healthcare footprint as the world's second-largest biotech fundraising hub. As Hong Kong's flagship innovation and technology ecosystem, HKSTP is home to more than 300 life and health technology companies and helps innovators turn pioneering ideas into real-world impact. Its ecosystem connects capital, talent, infrastructure and market access across the biotech innovation journey.

Photo Captions

Photo 1-2: In collaboration with InvestHK and HKTDC, HKSTP led a delegation of 41 park companies, institutes and spin-offs from five renowned local universities to showcase the Hong Kong's life and health technology innovations at BIO 2026 in San Diego.

Photo 3: HKSTP and LabCentral signed an MoU at BIO 2026 to strengthen ties and foster cross-border collaboration in life sciences ecosystem in both regions.

Photo 4-5: Terry Wong, CEO of HKSTP (3rd from right), introduced Hong Kong's vibrant life and health technology ecosystem to local partners and investors at the fireside chat moderated by Director of HKETO, D.C. Cheung (2nd from right) during the "Bio Nexus HK: From Showcase to Partnership" event organised by the Hong Kong Economic and Trade Office in San Francisco (HKETO San Francisco) and HKTDC. Other speakers included: Joe Panetta, President Emeritus of Biocom (3rd from left); Andy Wong, Head of Innovation & Technology and Life & Health Sciences of InvestHK (2nd from left); Curtis Louie, Director (New York & Midwest) of the HKTDC (1st from right); and Lucas Coleman, Director of World Trade Center San Diego (1st from left).

Photo 6-7: HKSTP CEO Terry Wong (6th from left back row in photo 6 and 4th from right in photo 7) and five Hong Kong university delegates visited the Salk Institute, home to six Nobel Laureates during BIO 2026 to explore partnerships and shape global biotech momentum through collaborative platforms.

Photo 8: HKSTP CEO Mr Terry Wong (1st from right) attended the "Translating Innovation Across Borders: Creating Global Gateways for Biotech Startups" panel sharing session at BIO 2026.

Photo 9: Immuno Cure – the developer of the first-in-human novel therapeutic HIV vaccine ICVAX – announced its collaboration with OPIS, an international Contract Research Organization (CRO), at BIO 2026

Photo 10: Zhaoke Ophthalmology signed an MOU with Laboratório Teuto to explore cross-border cooperation in ophthalmology.

Photo 11: Industry leaders, incubators, and venture capital firms – including Bayer Pharmaceuticals, Johnson & Johnson Innovation, LabCentral, Roche, Simcere Pharmaceutical, and T.Rx Capital – were invited to join the judging panel for startup pitching sessions.

###

Appendix: US BIO 2026 - List of 41 tech companies at Hong Kong Tech Pavilion including 9 non-HKSTP tech entities* (in alphabetical order)

No.	Company Name
1	Advent Gene Therapeutics*
2	AIMORPHOUS HEALTHTECH LIMITED
3	Alternative Bio Limited

4	AniTech Limited*
5	Bone's Technology Limited
6	BriWhite Limited*
7	Canton Biologics (Hong Kong) Limited
8	CATUG International (Hong Kong) Limited
9	CELLmeric Limited*
10	Cellomics Holdings Limited
11	Cimple Biotechnology Limited
12	Cognitact Limited
13	Cytomics Limited
14	Delonix Bioworks*
15	EnKang Pharmaceuticals (Guangzhou), Ltd.*
16	ETERN Health HK Limited
17	Excalipoint Therapeutics Hong Kong Limited
18	GenEditBio Limited
19	Great Bay Bio Limited
20	Greater Bay Area International Clinical Trial Institute (GBAICTI)*
21	HighTide Therapeutics (Hong Kong) Limited
22	Homing Therapeutics Limited
23	Hong Kong DPBIO Technology Limited*
24	Hong Kong Inhal Pharma Company Limited
25	HongKong Curegene Innovation Co., Limited
26	Hongkong Secretech Limited
27	Immuno Cure Holding (HK) Limited
28	InxMed (Hong Kong) Limited
29	Lee's Pharmaceutical (HK) Limited

30	MediOrigin Technology Limited*
31	Meta Pharmaceuticals (HK) Limited
32	NutrigeneAI Biotech Limited
33	Oncoimmunostics Ltd
34	Orange Biotech Limited
35	6J Biotechnology (Hong Kong) Limited
36	SPH Biotherapeutics (HK) Limited
37	Stemax Regenerative Medicine Technology Limited
38	StickyCell Hong Kong Limited
39	The Hong Kong Polytechnic University
40	RECORNA (HONGKONG) BIOTECHNOLOGY CO., LIMITED
41	Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Limited

###

About Hong Kong Science and Technology Parks Corporation

Hong Kong Science and Technology Parks Corporation (HKSTP) was established in 2001 to create a thriving I&T ecosystem grooming 13 unicorns, more than 17,000 research professionals and over 2,500 technology companies from 26 countries and regions focused on developing healthtech, AI and robotics, fintech and smart city technologies, etc.

Our growing innovation ecosystem offers comprehensive support to attract and nurture talent, accelerate and commercialise innovation for technology ventures, with the I&T journey built around our key locations of Hong Kong Science Park in Pak Shek Kok, InnoCentre in Kowloon Tong and three modern InnoParks in Tai Po, Tseung Kwan O and Yuen Long realising a vision of new industrialisation for Hong Kong, where sectors including advanced manufacturing, micro-electronics and biotechnology are being reimagined.

Hong Kong Science Park Shenzhen Branch in Futian, Shenzhen plays positive roles in connecting the world and the mainland with our proximity, strengthening cross-border exchange to bring advantages in attracting global talent and allowing possibilities for the development of technology companies in seven key areas: Medtech, big data and AI, robotics, new materials, microelectronics, fintech and sustainability, with both dry and wet laboratories, co-working space, conference and exhibition facilities, and more.

Through our R&D infrastructure, startup support and enterprise services, commercialisation and investment expertise, partnership networks and talent traction, HKSTP continues to contribute in establishing I&T as a pillar of growth for Hong Kong.

More information about HKSTP is available at www.hkstp.org.

Media Contact:

Hong Kong Science and Technology Parks Corporation
Angela Lau
Tel: +852 6535 7611
Email: angela.lau@hkstp.org

Edelman Public Relations
Derrick Kwan
Tel: +852 2837 4718 / 6855 0798
Email: derrick.kwan@edelman.com / Edelmanhkstppr@edelman.com